Repligen (NASDAQ: RGEN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Repligen Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Repligen Company Info
A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.
News & Analysis
The company is coming off a solid third quarter and is getting noticed by analysts.
The bioprocessing equipment company is seeing growth prospects accelerate for its non-COVID-related revenue.
Repligen's strong second-quarter results are a hit with investors.
A stronger-than-expected earnings report calls months of the stock's weakness into question.
Management has executed its strategy well, but a potential risk is looming.
Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.
These two companies offer under-the-radar ways to invest in the healthcare space.
It looks like the gene therapy market is a haunted house, but growing biotech Repligen might be the treat investors need this Halloween.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/24/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
RGEN earnings call for the period ending September 30, 2021.
RGEN earnings call for the period ending June 30, 2021.
RGEN earnings call for the period ending March 31, 2021.
RGEN earnings call for the period ending March 31, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.